Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Mumps virus RNA-dependent RNA polymerase (RdRp), primarily encoded by the Large (L) protein, is the central catalytic component of the viral replication machinery [1]. It operates within a complex with the viral phosphoprotein (P) to execute two distinct processes: the transcription of viral genes into messenger RNAs and the replication of the negative-sense genomic RNA [2]. The L protein is a multifunctional enzyme that includes domains for RNA polymerization, as well as the enzymatic activities required for 5' capping (guanylyltransferase and methyltransferase) and 3' polyadenylation of viral transcripts [1,3]. Because the mumps virus causes significant morbidity, including parotitis, orchitis, and aseptic meningitis, the RdRp is a critical target for therapeutic intervention [4]. Since humans lack a direct homolog to this viral enzyme, inhibitors can achieve high selectivity, minimizing damage to host cells [5]. While the mumps vaccine is highly effective, the development of RdRp inhibitors like Favipiravir remains vital for treating severe cases and managing outbreaks in populations with waning immunity [6]. Sources: [1] UniProt Consortium. UniProtKB - P19123 (L_MUMPV). [2] Whelan, S. P., et al. (2004). Transcription and replication of nonsegmented negative-strand RNA viruses. Current Topics in Microbiology and Immunology. [3] Morin, B., et al. (2013). The polymerase of negative-strand RNA viruses. Antiviral Research. [4] Hviid, A., et al. (2008). Mumps. The Lancet. [5] Furuta, Y., et al. (2013). Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research. [6] de Vries, R. D., et al. (2021). Mumps virus: an update on the epidemiology, pathogenesis, and potential antivirals. Journal of Clinical Virology.
Inhibition of viral RNA synthesis through competitive inhibition of the polymerase active site or premature chain termination during RNA polymerization.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mumps virus RNA-dependent RNA polymerase (MuV RdRp).